{
    "nctId": "NCT00088972",
    "briefTitle": "S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women",
    "officialTitle": "Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Mammographic Density",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At elevated risk of developing breast cancer, as defined by 1 of the following:\n\n  * Modified Gail risk at 5 years \u2265 1.7% or lifetime risk \u2265 20% AND Claus Model, BRCAPro Model, or Tyrer-Cuzick Model lifetime risk \u2265 20%\n  * Diagnosis of lobular carcinoma in situ or ductal carcinoma in situ\n  * Known deleterious mutation of BRCA1 or BRCA2\n* At least 1 breast available for imagery and biopsy\n* Has undergone a baseline mammogram with a standard density wedge within 7-14 days after completion of the last menstrual period AND within 7 days before study entry\n\n  * Mammogram normal or benign (BIRADS score 0 or 1)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal, defined by 1 of the following criteria:\n\n  * Last menstrual period \\< 6 months ago AND no prior bilateral ovariectomy AND not on estrogen replacement therapy\n  * Prior hysterectomy (with ovaries still in place) AND normal follicle-stimulating hormone levels within 28 days of study entry\n\nPerformance status\n\n* Zubrod 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Bilirubin \\< 2.0 times institutional upper limit of normal (IULN)\n* SGOT or SGPT \\< 2 times IULN\n* Alkaline phosphatase \\< 2 times IULN\n* INR \u2264 1.5\n* PT and PTT \u2264 IULN\n\nRenal\n\n* Serum creatinine \\< 2.0 times IULN\n\nCardiovascular\n\n* No history of myocardial infarction\n* No angina pectoris\n* No known coronary artery disease\n* No history of stroke or mini-stroke (e.g., transient ischemic attack)\n* No history of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism)\n* No uncontrolled hypertension (i.e., blood pressure \\> 140/90 mmHg)\n\nPulmonary\n\n* No asthma after taking aspirin or other NSAIDs\n\nOther\n\n* No known sensitivity to celecoxib\n* No allergy to sulfonamides\n* No urticaria or allergic-type reactions after taking aspirin or other NSAIDs\n* No extreme lactose intolerance\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or early bladder cancer (preinvasive transitional cell carcinoma of the bladder)\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 5 years since prior biologic therapy for cancer\n\nChemotherapy\n\n* More than 5 years since prior chemotherapy for cancer\n\nEndocrine therapy\n\n* At least 28 days since prior tamoxifen\n* No prior systemic estrogen modifiers (SERMs) or aromatase inhibitors\n* Concurrent hormonal contraception (i.e., pills, patches, or shots) allowed provided contraception was initiated prior to study entry\n\nRadiotherapy\n\n* No prior radiotherapy to the breast to be studied\n\nSurgery\n\n* Not specified\n\nOther\n\n* At least 7 days since prior anticoagulant therapy\n* More than 1 month since prior chronic daily aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) of more than 7 days duration\n\n  * Concurrent intermittent aspirin or NSAIDs allowed (no more than 10 days per month)\n* No concurrent participation in another clinical trial for treatment or prevention of cancer unless no longer receiving treatment and is in the follow-up phase",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}